Market Intelligence, Clinical Progress, and High-Purity Reagents for Facioscapulohumeral Muscular Dystrophy (FSHD) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DUX4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DUX4 Recombinant Protein (Full-length & Homeodomain Fragments) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. |
View DUX4 Products |
| Gene Delivery | DUX4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and target engagement assays. |
View DUX4 Products |
| Benchmark Ab | Anti-DUX4 Monoclonal Antibody Recombinant research-grade control for Western blot, IF, and ChIP. |
View DUX4 Products |
| Validator | DUX4 siRNA Set For knockdown verification and assay specificity controls. |
View DUX4 Products |
| Related Target A | SMCHD1 Epigenetic repressor of the D4Z4 locus; synergistic target for FSHD combination therapy. |
View SMCHD1 Products |
| Related Target B | KDM4A Histone demethylase regulating D4Z4 chromatin accessibility; critical for DUX4 expression mechanisms. |
View KDM4A Products |
| Related Target C | MAPK14 (p38 alpha) Upstream regulator of DUX4 expression; target for indirect inhibition. |
View MAPK14 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Human vs Murine Ortholog Specificity | Human DUX4 and Murine Dux recombinant proteins available with >95% purity, Sequence Verified for species-specific assay calibration. |
| DUX Family Counter-screening | Homolog panel proteins (DUX4, DUX4c) strictly Sequence Verified to ensure off-target liability screening for ASOs and antibodies. |
| Intracellular Target Engagement | Lentivirus Premade Particles for stable DUX4 expression cell line construction. |
| Biochemical Inhibitor Screening | High-Purity (>95%) expressed DUX4 protein with strict MW verification. |
| Lack of Controls | Research-grade benchmark antibodies and siRNA sets included as assay controls. |
| False Positives | Sequence-verified siRNA included for target-specificity checks in reporter and knockdown assays. |
Live DUX4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DUX4 therapeutics is intensifying, with major players shifting focus from traditional small molecules to RNAi and Antisense Oligonucleotides (ASOs). First-generation antisense and epigenetic repression strategies are advancing through preclinical and early clinical stages. The next wave of R&D is targeting direct muscle-tissue delivery platforms (such as TfR1-conjugated oligonucleotides) to safely and efficiently silence aberrant DUX4 expression in skeletal muscle, alongside combinatorial chromatin modulation approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Fulcrum Therapeutics | FSHD | Reporter Assays (Need Stable Cell Lines) |
| siRNA / AOC | Avidity Biosciences, Arrowhead | FSHD | Knockdown Validation (Need High-Purity Controls & siRNA) |
| ASO / Gene Edit | Dyne Therapeutics | Muscular Dystrophy | Target Engagement (Need Sequence-Verified ORF) |